immunotherapy for inflammaging
Very little changed between June 24, 2021 and February 1, 2023. HCW Biologics kept saying the same basic thing: inflammaging matters, and immunotherapy is the tool they intend to use against it. That is continuity, not a pivot. What stayed stable is the core belief. The company continued to frame age-related chronic inflammation as a real biological problem worth targeting, rather than a marketing garnish stapled onto a broader platform. The proposed answer also stayed the same: immunotherapy, not a last-minute rebrand into something trendier. What changed is mostly the wording, at least from the evidence here. Both snapshots describe substantially the same position, and neither gives enough detail to show whether the science, target selection, or development strategy matured in a meaningful way. So the honest read is boring but clean: stable thesis, thin evidence on deeper evolution.